Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
For Postpartum Hemorrhage Acute Management, frame the differential by acuity and pathophysiology, then align diagnostics to the leading hypotheses. Prioritize stabilization while obtaining high‑yield studies such as CBC (Baseline hematology), BMP (Electrolytes/renal). Incorporate bedside imaging and targeted labs to define severity and identify complications; synthesize results with clinical trajectory to refine the working diagnosis and disposition needs.
Treatment Strategy & Disposition
Initiate disease‑directed therapy alongside supportive care, titrating to objective response. Pharmacologic options commonly include Analgesia/Antipyretics. Use validated frameworks (e.g., Uterotonics (Examples)) to guide escalation and site of care. Address precipitating factors, de‑escalate empiric therapies with data, and arrange follow‑up for monitoring and risk‑factor modification; admit patients with instability, high risk of deterioration, or needs for close monitoring.
Epidemiology / Risk Factors
- Risk factors vary by condition and patient profile
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| CBC | Baseline hematology | Abnormal counts | |
| BMP | Electrolytes/renal | Derangements |
Uterotonics (Examples)
| Agent | Dose | Contraindications |
|---|---|---|
| Oxytocin | 10 IU IM or infusion per protocol | — |
| Methylergonovine | 0.2 mg IM | Hypertension, preeclampsia |
| Carboprost | 250 mcg IM q15–90 min (max 2 mg) | Asthma |
| Misoprostol | 600–800 mcg PO/SL/PR | Use per local protocol |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Oxytocin | Uterotonic (oxytocin receptor) | Minutes | First-line uterine atony | Water intoxication (rare); pregnancy/lactation considerations |
| Tranexamic acid | Antifibrinolytic | Hours | Adjunct within 3 h | Thrombosis risk; pregnancy/lactation considerations |
| Methylergonovine | Ergot alkaloid | Minutes | Second-line uterotonic (avoid HTN) | Hypertension, vasospasm; pregnancy/lactation considerations |
| Carboprost | PGF2α analog | Minutes | Third-line uterotonic (avoid asthma) | Bronchospasm; pregnancy/lactation considerations |
Prognosis / Complications
- Prognosis depends on severity, comorbidities, and timeliness of care
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
Notes
Warm the patient and products; maintain ionized calcium with transfusion. Early obstetrics and anesthesia involvement is critical.